Stacker ranks the 100 least popular jobs in America, using data from the Bureau of Labor Statistics. Click for more.
Yet about 36% of young adults under age 35 say they don t plan on getting a Covid-19 vaccine, according to a recent Quinnipiac University poll.
That s a major problem because: Even if life is already starting to look more normal, the US will never reach herd immunity if young adults don t step it up. Health experts say we need at least 70% to 85% of the US population immunized to reach herd immunity and get this pandemic under control. By not getting vaccinated, young adults could make vaccines less effective for their friends, family and everyone else. (More on that later.)
The vaccine, made of nanoparticles, offers broad protection against different viral strains.
Recurring seasonal flu epidemics and potential pandemics are among the most severe threats to public health. Current seasonal influenza vaccines induce strain-specific immunity and are less effective against mismatched strains. Broadly protective influenza vaccines are urgently needed.
Intranasal vaccines are a promising strategy for combatting infectious respiratory diseases, such as influenza. They are more effective than vaccines injected into a muscle because they can induce mucosal immune responses in respiratory tracts, preventing infection at the portal of virus entry. They can also stimulate systemic immune responses throughout the body.
Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
May 3, 2021 GMT
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
PARIS (BUSINESS WIRE) May 3, 2021
Regulatory News:
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that
Print
Carey Alexander Washington, 80, a practicing clinical psychologist, called his daughter in January as soon as he received his first dose of the Pfizer COVID-19 vaccine.
“He was just so excited that he had gotten it,” said Tanya Washington, 49, a resident of Atlanta who works at an investment firm.
Carey received his second shot Feb. 4. A little more than a month later, the South Carolina resident experienced shortness of breath. His internist did not test him for the virus. Carey, after all, was fully vaccinated. The doctor sent him to a cardiologist instead, who also didn’t test for the coronavirus.